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Summary. The variation in immune responses to 
standard inoculation of the hepatitis-B virus vac- 
cine suggest hat host factors influence response 
in ways that are not presently understood. We 
studied 25 low/nonresponding health care workers 
(anti-HBs titer < 50 IU/1) after the third inocula- 
tion of an experimental hepatitis-B vaccine to de- 
termine their immune status (through lymphocyte 
phenotypes) and HLA type. After application of 
a fourth inoculation, the seroconverting subjects 
showed only low anti-HBs levels; three male sub- 
jects remained anti-HBs negative. Twelve months 
after the fourth inoculation only 9 of 25 subjects 
(36%) maintained anti-HBs titer >10 IU/1. Al- 
most all subjects had normal B-cell and CD-4 and 
CD-8 counts and ratios. Relative to ther Europe- 
an populations HLA-A-10 (P<0.05), B-12 (P< 
0.025), CW-5 (P<0.05), DR-3 (P<0.025), and 
DR-5 (P<0.025) were increased, whereas DR-2 
(P<0.05) was decreased. However, after correc- 
tion of the P-values for the number of HLA anti- 
gens determined, these differences were no longer 
significant. Furthermore, these HLA types were 
not the same as those reported in other studies 
(except for DR-3). We suggest that larger sample 
sizes or even not yet available immunogenetic 
markers wilt be required to prove an"  immunogen- 
etic background" in low/nonresponders, if it ex- 
ists. 
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HBV infection with its complications - fulminant 
course, chronicity, and development of hepatocel- 
Abbreviations: anti-HBc = antibody to hepatitis-B core antigen; 
anti-HBs = antibody to hepatitis-B surface antigen; HBsAg= 
hepatitis-B surface antigen 
lular carcinoma - remains a major public health 
problem even in areas of low prevalence, such as 
Europe and the United States. To minimize this 
risk, HBV vaccination has been recommended for 
groups at high risk, such as health care workers. 
However, the 3%-5% of healthy persons who fail 
to respond to active immunization against HBV 
infection offer a challenge for research [6, 24]. 
The lack of immune response to HBsAg may 
be related to genetic factors, since female vaccine 
recipients usually develop higher antibody levels 
against HBsAg than do males [13]. On the other 
hand, the immune defect of hemodialysis patients 
and other immunocompromised patients may be 
a more general one, causing seronegative rates of 
up to 40% [3, 7, 22, 10]. 
Is there an "immunogenetic background" for 
nonresponsiveness in active immunization against 
hepatitis-B virus (HBV) infection? 
Better understanding of the immune response 
regulation towards a complex peptide antigen 
(HBsAg) in man may provide new strategies for 
the preparation of a synthetic vaccine that circum- 
vents nonresponsiveness. 
Methods 
Participants 
Between October 1982 and July 1983, 217 health 
care workers were inoculated three times with an 
experimental hepatitis-B vaccine. The vaccination 
schedule was: first inoculation at 0, second inocu- 
lation at 1 month after the first inoculation, and 
third inoculation 5 months after the first inocula- 
tion. Each subject was given a total of 120 pg 
HBsAG in the deltoid region. All participants de- 
nied prior hepatitis, were serologically negative for 
HBsAg, anti-HBs, and/or anti-HBc prior to first 
inoculation and all had normal transaminase lev- 
els. 
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Four percent of the test subjects (6males and 
3 females) did not seroconvert, i.e., they developed 
anti-HBs titers below 3 IU/1 (nonresponders). 
Fourteen percent of the subjects (22 males and 
9 females) developed anti-HBs titers above 3 IU/1 
and below 50 IU/1 (low responders). The immune 
response showed a definite dependence on the sex
and age of the vaccinated subjects. Males and older 
persons produced significantly lower anti-HBs 
titers. These data have been published previously 
[13]. 
Of the 40 subjects with anti-HBs titers below 
50 IU/1 after the third inoculation, 25 (6 nonre- 
sponders, 4 male and 2 female; and 19 low re- 
sponders, 13 male and 6 female) were located 
1 year later and are the subjects of this report. The 
median age of the 17 males was 36 years (range, 
30-53 years), and the median age of the 8 females 
was 31 years (range, 23-46 years). A comparison 
of different characteristics revealed that the low/ 
nonresponders consisted of significantly more 
males than the responders (P= 0.046, Fisher's Ex- 
act Test, two-tailed). 
Revaccination and Anti-HBs Titer 
These 25 low/nonresponders were revaccinated a 
fourth time with the same experimental hepatitis-B 
vaccine (40 pg HBs Ag per dose) intramuscularly 
in the deltoid region approximately ] year after 
the third inoculation. At 3 weeks and at 1 year 
after the fourth inoculation, sera were obtained 
for anti-HBs titers, as determined by radioimmu- 
noassay (AUSAB, Abbott Laboratories, North 
Chicago, Ill.). International units per liter were cal- 
culated according to the formulas developed by 
Hotlinger [9]. 
Immunologic and Genetic Methods 
B lymphocytes and T3-, T4-, and Ts-lymphocyte 
populations were determined as has been pre- 
viously described [8]. From these data, T4/T8 ratios 
were calculated. 
HLA-A, -B, -C, and -DR antigens were deter- 
mined by the standard two-step microlymphocyto- 
toxicity test according to Terasaki and McCMland 
[25] using the modification by van Rood [26]. A 
comparison was made with the results on more 
than 2500 Europeans [12] whose distribution of 
HLA antigens was very similar to that of healthy 
blood donors tested at this hospital. 
Statistics 
Statistical assessment of the frequency of HLA- 
antigens was done using the chi-square test and 
Yate's correction [1]. Adjustment of the P-values 
was done according to Svejgaard, which involved 
multiplying the P-values by the number of antigens 
tested [23]. 
Results 
Revaccination 
Three weeks after the fourth inoculation, three 
male participants (12%) had not produced an anti- 
HBs titer above 3 IU/I. The remaining 22 (88%) 
showed titers between 3.6 and 1231 IU/1 (Fig. 1). 
Twelve months after the fourth inoculation the 
titer of anti-HBs had declined markedly (Fig. 2). 
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Fig. 1. Distribution of anti-ttBs titers 3 weeks after the fourth 
inoculation. Note the relatively low anti-HBs levels. Three male 
participants still remained nonresponders (anti-HBs titers 
< 3 IU/I). The highest iter was 1231 IU/I; n = number 
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Fig. 2. Distribution of anti-HBs titers 12months after the 
fourth inoculation. Note the marked titer decline. Sixteen par- 
ticipants had anti-HBs titers < 10 IU/I; n = number 
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Table 1. HLA-DR frequencies of the low/nonresponders. DR3 and DR5 were found to be increased, whereas DR2 was decreased. 
Note, however, that significance did not hold up after the P-values were corrected by the number of determined HLA antigens 
(cp*= corrected P). Controls were taken from a European population analysis [I 2]; OR, odds ratio; n.s., not significant 
Antigen Low/nonresponders (n = 25) 
N % 
Controls (n = 2499) OR P cp* 
n % OR p cp* 
DR1 4 16,7 332 13,3 1.30 >0.05 n.s. 
DR2 2 8.3 627 25.1 0.27 < 0.05 < 2.35 
DR3 10 41.7 509 20.4 2.80 < 0.025 < i .8 
DR4 6 25.0 457 18.3 1.49 > 0.05 n.s. 
DR5 10 41.7 487 19.5 2.95 < 0.025 < i .8 
DRw6 1 4,2 107 4,3 0.97 > 0.05 n.s. 
DR7 5 20.8 584 23.4 0.86 > 0.05 n.s. 
DRw8 1 4.2 135 5.4 0.76 > 0.05 n.s. 
DRw9 1 4.2 55 2.2 1.93 > 0.05 n,s. 
DRwl0 0 0 35 1.4 >0.05 n.s. 
Twelve subjects (48%) were now anti-HBs negative 
(anti-HBs less than 3 IU/1). Sixteen subjects (64%) 
showed anti-HBs titers _< 10 IU/1, which is felt to 
be the minimum effective titer against hepatitis-B 
virus infection. The anti-HBs titer of 8 other parti- 
cipants (32%) ranged from 11 IU/1 to 40 IU/1. 
Only i subject showed a markedly high antibody 
titer of 155 IU/1. No subject with anti-HBs titers 
of > 200 IU/1 3 weeks after the fourth inoculation 
decreased to < 10 IU/1 during the 12 months after 
that inoculation. 
Immunologic Studies 
Most subjects had normal T3- (median 1260, range 
470-3270/mm3), T4- (median 770, range 
188-2240/mm3), and Ts-lymphocyte (median 376, 
range 120-1470/mm 3) counts. Only 1 subject had 
a low T4-cell count (188 cells/mm3). The T4/T8 ra- 
tio was < 1 in this and in another subject who 
had an increased Ts-cell count (1470/mm3). Since 
antibody synthesis requires B cells, we also deter- 
mined these quantitatively (median 175, range 
42-590/mm3). Only 1 subject, different from the 
above-mentioned ones, showed a reduced B-cell 
count (only 42/mm3). Neither difference was stat- 
istically significant. Clinically and serologically, 
there was no evidence of acute or chronic infection, 
nor of a general immunodeficiency in these sub- 
jects. 
Histocompatibility Testing 
The 25 participants were examined for their HLA- 
A, -B, and -C antigens and 24 were examined for 
HLA-DR antigens. The DR typing was not suc- 
cessful in 1 subject. For controls, we used the data 
from a European population analysis in which 
more than 2500 European sera were typed [12]. 
A-10 (P<0.05), B-12 (P<0.025), and CW-5 
(P<0.05) were found to be increased. DR-2 ex- 
pression was decreased (P<0.05) and DR-3 (P< 
0.025) and DR-5 (P<0.025) were increased (Ta- 
ble 1). However, the P-values were no longer sig- 
nificant after correction for the number of HLA 
antigens determined. 
Discussion 
Hepatitis-B vaccine is made of purified HBsAg 
prepared from the plasma of chronic HBsAg carri- 
ers. Several factors are known to be associated with 
diminished antibody responsiveness to vaccina- 
tion. The immune response is usually excellent in 
females and young recipients, but decreases with 
age. Males evidence significantly lower anti-HBs 
levels than females [13, 28]. Hemodialysis and im- 
munosuppression negatively affect immune re- 
sponse to vaccination [3, 7, 22, 10]. 
We administered a fourth inoculation to 25 
health care workers who had no or only a minor 
immune response after three inoculations. Three 
subjects failed to respond at all to the fourth inocu- 
lation. Only 9 persons (36%) remained protected 
(>10 IU/1 anti-HBs) 12 months after the fourth 
inoculation. Similar findings among poor re- 
sponders were also reported by Craven and co- 
workers using a different vaccine preparation [5]. 
On the other hand, among normal responders only 
8.7% fell to unprotective l vels over 12months 
[11]. Generally, levels of anti-HBs following immu- 
nization predict levels 12 months later. 
There were no significant changes of total lym- 
phocytes and lymphocyte subpopulatons. Thus, 
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the immune defect in the low/nonresponders seems 
to be specific for HBsAg and does not indicate 
a general immunodeficiency. 
Patients with chronic hepatitis-B virus infection 
are known to be hyporesponsive to HBsAg, as 
were these study participants. The low response 
has been attributed to decreased T4/Ts-lympho- 
cyte ratios due to elevated Ts-lymphocyte cell 
counts in chronic hepatitis-B. Activation of T8 
lymphocytes by HBsAg has therefore been postu- 
lated to be responsible for the absence of anti-HBs 
production [2, 14]. However, in our study T8 levels 
were almost all in the normal range. 
The immune response of HBsAg appears to be 
regulated by genetic factors. Milich and Neurath 
and co-workers have elucidated the complex regu- 
latory mechanisms by studying high responder and 
low/nonresponder mice [16-211]. After crossbreed- 
ing experiments, it was possible to identify haplo- 
type H-2 q'a as high responders, haplotype H-2 ='b, k
as intermediate o low responders, and haplotype 
H-2 =' f as nonresponders. Furthermore, immune re- 
sponses are governed by two immune response (Ir) 
genes, one in the I-A subregion (Ir-HBs-1) and 
one in the I-C subregion (Ir-HBs-2) of the murine 
H-2 complex. Ir-HBs-I regulates the primary re- 
sponses to all HBsAg determinants, whereas the 
influence of Ir-HBs-2 is determinant-specific, af- 
fecting the responses to the d or y determinants. 
Our results suggest evidence for an "immuno- 
genetic background" regulating the immune re- 
sponse to HBsAg in man. In this study, A-10, B-12, 
CW-5, DR-3, and DR-5 were found to be in- 
creased in histocompatibility testing, whereas DR- 
2 was decreased. With regard to DR-3, this is in 
agreement with Craven et al. [5]. Paradoxically, an 
increased frequency of HLA-DR-3 was also seen 
in patients with autoimmune chronic active hepati- 
tis [15]. Usually, one would expect patients with 
autoimmune diseases to be high responders instead 
of low responders. Our results differ f om Craven 
et al. [5], Cooksley et al. [4], and Walker et at. [27] 
with regard to DR-7, which they found elevated. 
However, these authors did not correct their 
P-values according to the number of determined 
HLA antigens [23]. After performing this correc- 
tion, the above-mentioned differences in our study 
no longer remained significant. Thus, our results 
may only be suggestive of trend differences in the 
frequency of HLA antigens in nonresponders to
HBsAg. The different findings in various studies 
may indicate that most associations were due to 
chance. Furthermore, the conflicts between the 
various reports suggest that better immunogenetic 
markers will be necessary for a clear indication 
of a genetic regulatory mechanism, such as is indi- 
cated in the mouse model. 
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